HemoGenix, Inc

HemoGenix specializes in contract services and assays for toxicity testing, stem cell research and stem cell therapeutic quality and potency testing.

08/21/2025

Eliminate the Potential of Pre-Clinical Surprises

Even with extensive measures taken to reduce unwanted and occasionally uninterpretable pre-clinical data, such issues may still arise, leading to substantial complications.

At HemoGenix®, our priority is to predict toxicity—particularly within the lympho-hematopoietic system- before unexpected pre-clinical results arise. When such challenges do occur, we are ready to support you as a trusted contract research partner.

Learn more: https://conta.cc/4oKCI0w

08/13/2025

In Vitro Primary Cell Toxicity Screening

Early in vitro screening of compounds against primary target cells can provide a wealth of information to help reduce drug development time and cost. When targeted to specific primary cell populations that might exhibit potential toxicity, such information early on in drug development, can be a game changer. In addition, in vitro assessment of drug combinations and the ability to compare toxicity profiles using the same readout, can significantly streamline the drug development process.

For more information, visit www.hemogenix.com or contact us directly at screening@hemogenix.com or by calling 719-264-6250. We look forward to assisting you.

07/30/2025

Immunotoxicity and Immune Cell Testing
https://conta.cc/41l74g2

06/24/2025

In Vitro Drug Combination and Interaction Studies

HemoGenix® provides the ability to look at the effect of drug combinations and interactive responses using primary cells and its proprietary in vitro assays. This approach allows for a more comprehensive understanding of how drugs might interact within the human body, potentially leading to more effective and safer therapeutic strategies.

Learn more: https://conta.cc/3ZNmJ7j

06/11/2025

HemoGenix has developed proprietary in vitro assays to study various aspects of the immune systems.

> HALO-Tox HT to study the effects of test compounds on common lympho-hematopoietic stem cells and progenitor cells of the T- and B-lymphocyte lineages.

> ImmunoGLO™ is an in vitro assay used to study lymphocyte proliferation or cytotoxicity.

> ImmunoGLO™-TCP is an in vitro assay platform specific for T-lymphocytes.

> ImmunoGLO™-BCP is an in vitro assay platform specific for B-lymphocytes.

> ImmunoGLO™-MLC is an in vitro 1- or 2-way mixed lymphocyte reaction platform

All of these platforms can be combined or multiplexed with flow cytometry or other readouts to study multiple facets of immunotoxicity including Cytokine Release Syndrome, Tregs, ADCC, ADC and others.

Learn more:https://hemogenix.com/Invitro_Immuno.php

06/05/2025

Mechanism of Action Studies

Knowing how and why a particular drug acts on a specific cell type or biological system is of prime importance in understanding the response. HemoGenix has the ability to study the response of specific cell populations and is also capable of investigating the Mechanism of Action (MOA) that occurs in those populations, thereby providing greater predictive toxicological information.

Learn more: https://hemogenix.com/Mechanism_of_Action.php

05/27/2025

MSCGlo™-Tox HT is a fully standardized and validated ATP bioluminescence (customized CellTiter-Glo® from Promega) toxicity assay that measures functional viability of cells based on intracellular ATP (iATP) concentrations. In short, MSCGlo™-Tox HT is a metabolic viability assay designed specifically for MSCs.

Learn more: https://hemogenix.com/MSC_Toxicity.php

05/21/2025

In Vitro High-Throughput Stem and Progenitor Cell Hematotoxicity Screening for any stage of drug development from screening to clinical trials.

Learn more: https://hemogenix.com/Hemotoxicity.php

05/13/2025

Cytokine Release Assays

Immunotoxicity represents a diverse set of studies that includes Cytokine Release Assays (CRAs) to understanding whether a new drug candidate will elicit an inflammatory response. Cytokine Release Assays help ensure safety of a new drug or therapy so that phenomena such as the cytokine storm can be predicted.

Learn more: https://conta.cc/4meCfT3

04/30/2025

High-Throughput Toxicity Screening

From high-throughput early screening to deciphering surprise results during pre-clinical and initial clinical studies, HemoGenix® is a trusted contract research partner during all stages of drug development.

Learn more: https://conta.cc/3ESDdDF

04/23/2025

Comparative In Vitro Cytotoxicity Screening

Toxicity can be discovered at any stage of drug development. However, the later this occurs in the pipeline, the greater the effort and the more costly the process becomes. Therefore, the earlier potential cytotoxicity is discovered, the better.

Learn more: https://conta.cc/4jDn6bO

04/08/2025

3-Way In Vitro Toxicity Testing

HemoGenix® has been instrumental in helping our world-wide partners bring new drugs to market and evaluate the safety of existing medications, products and environmental agents. Our in vitro toxicity testing is performed using a number of different cell and tissue types as well as species. Contract research services are flexible, tailored and integrated depending on our client's needs. Many of our testing capabilities use proprietary in vitro assays platforms and include:

>> Early in vitro toxicity high throughput screening
>> Drug-drug interaction (DDI) studies
>> In vitro comparative toxicity testing

Additional testing models are also available. Learn more: https://conta.cc/4chyKXE

Address

Colorado Springs, CO

Telephone

+17192646250

Website

http://www.hemogenix.com/

Alerts

Be the first to know and let us send you an email when HemoGenix, Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Purple Mountain Recovery
3225 Austin Bluffs Pkwy Ste 100
Optimal Wellness Solutions
80919